Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Day One Biopharmaceuticals Inc (DAWN)

Day One Biopharmaceuticals Inc (DAWN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Day One to Present at the 43rd Annual J.P. Morgan Healthcare Conference

DAWN : 12.79 (+2.65%)
Day One Announces Retirement of Dr. Samuel Blackman, Co-Founder and Head of Research & Development

DAWN : 12.79 (+2.65%)
Day One to Participate in the Piper Sandler 36th Annual Healthcare Conference

DAWN : 12.79 (+2.65%)
Day One Biopharmaceuticals (DAWN) Stock Soars 11.3% on Strategic Milestones and Promising Outlook

Shares of Day One Biopharmaceuticals (NASDAQ: DAWN) surged 11.3% this morning, reflecting strong investor confidence fueled by a series of favorable developments. This biotech firm focused on advancing...

DAWN : 12.79 (+2.65%)
Day One Reports Third Quarter 2024 Financial Results and Corporate Progress

DAWN : 12.79 (+2.65%)
Day One to Report Third Quarter 2024 Financial Results Wednesday, October 30, 2024

DAWN : 12.79 (+2.65%)
Day One Biopharmaceuticals (DAWN) Stock Soars 11.3% on Strategic Milestones and Promising Outlook

Shares of Day One Biopharmaceuticals (NASDAQ: DAWN) surged 11.3% this morning, reflecting strong investor confidence fueled by a series of favorable developments. This biotech firm focused on advancing...

DAWN : 12.79 (+2.65%)
KAZIA THERAPEUTICS ANNOUNCES PHASE II CLINICAL STUDY TO INVESTIGATE PAXALISIB IN RECURRENT/PROGRESSIVE IDH-MUTANT GRADE 2 & 3 GLIOMA

/PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that it is supporting...

KZIA : 3.02 (-0.33%)
DAWN : 12.79 (+2.65%)
NVS : 97.11 (+0.35%)
Stock Index Futures Muted as Weak China Trade Data Weighs on Sentiment

June S&P 500 futures (ESM23) are up +0.14%, and June Nasdaq 100 E-Mini futures (NQM23) are up +0.09% this morning as weak trade data from China stoked investor concerns over the strength of global demand....

ESM23 : 4,453.35s (+0.61%)
NQM23 : 15,316.61s (+0.85%)
PACW : 7.54 (-2.71%)
WAL : 84.62 (+2.12%)
INTC : 19.52 (+2.41%)
AMD : 119.21 (+0.28%)
COIN : 278.71 (+1.75%)
ITX.E.DX : 50.070 (+1.32%)
YEXT : 6.38 (+0.31%)
GDYN : 20.50 (+0.44%)
VXRT : 0.6196 (+2.70%)
DAWN : 12.79 (+2.65%)
Why Shares of Day One Pharmaceuticals Are Up Monday

The clinical-stage biotech released early trial news regarding its lead therapy candidate.

DAWN : 12.79 (+2.65%)

Barchart Exclusives

Scalp a 47% Payout by the End of This Week with Micron (MU) Call Spreads
Yes, there are serious questions about MU stock following the underlying company’s disappointing earnings but a steady march is all options traders need. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar